ArticleFASEB journal : official publication of the Federation of American Societies for Experimental Biology2016
Divergent shifts in lipid mediator profile following supplementation with n-3 docosapentaenoic acid and eicosapentaenoic acid.
Article in FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 1 synthesis or guideline pooled it, 83 citations in OpenAlex.
- Maresin: Macrophage Mediator for Resolving Inflammation and Bridging Tissue Regeneration-A System-Based Preclinical Systematic Review.International journal of molecular sciences · 2023Pooled it
- Oxylipin serum profile changes in response to an open-label anti-inflammatory dietary intervention.Clinical nutrition ESPEN · 2025Trial
- Long-chain Polyunsaturated Fatty Acids MitigatebioRxiv : the preprint server for biology · 2026Article
- Neutrophil efferocytosis in chronic inflammatory gastrointestinal diseases: mechanistic insights and therapeutic potential.Frontiers in immunology · 2026Review
- DPA/AA ratio as a potential biomarker of primary aldosteronism in young and middle-aged adults.Frontiers in endocrinology · 2026Article
- Plasma oxylipins in children with sickle cell disease: Associations with biomarkers of inflammation and endothelial activation.Prostaglandins, leukotrienes, and essential fatty acids · 2025Article
- Article
- Navigating my career in lipid research.European journal of clinical nutrition · 2025Review
- High-fiber basil seed flour reduces insulin resistance and hepatic steatosis in high-fat diet mice.NPJ science of food · 2024Article
- "A Time to Tear Down and a Time to Mend": The Role of Eicosanoids in Atherosclerosis.Arteriosclerosis, thrombosis, and vascular biology · 2024Article
- Associations of Plasma Omega-3 Fatty Acids With Progression and Survival in Pulmonary Fibrosis.Chest · 2024Article
- Metabolic Patterns of High-Invasive and Low-Invasive Oral Squamous Cell Carcinoma Cells Using Quantitative Metabolomics andBiomolecules · 2023Article
- Maternal DHA intake in mice increased DHA metabolites in the pup brain and ameliorated MeHg-induced behavioral disorder.Journal of lipid research · 2023Article
- Eicosapentaenoic Acid Influences the Lipid Profile of an In Vitro Psoriatic Skin Model Produced with T Cells.Biomolecules · 2023Article
- Article
- Development of sustainable downstream processing for nutritional oil production.Frontiers in bioengineering and biotechnology · 2023Review
- Crystalline silica-induced proinflammatory eicosanoid storm in novel alveolar macrophage model quelled by docosahexaenoic acid supplementation.Frontiers in immunology · 2023Article
- Potential Mechanisms by Which Hydroxyeicosapentaenoic Acids Regulate Glucose Homeostasis in Obesity.Advances in nutrition (Bethesda, Md.) · 2022Review
- Polyunsaturated fatty acids and fatty acid-derived lipid mediators: Recent advances in the understanding of their biosynthesis, structures, and functions.Progress in lipid research · 2022Review
- Specialized Pro-Resolving Lipid Mediators: New Therapeutic Approaches for Vascular Remodeling.International journal of molecular sciences · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 3 countries.
Funding
Abstract
In contrast to the well-characterized effects of specialized proresolving lipid mediators (SPMs) derived from eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), little is known about the metabolic fate of the intermediary long-chain (LC) n-3 polyunsaturated fatty acid (PUFA) docosapentaenoic acid (DPA). In this double blind crossover study, shifts in circulating levels of n-3 and n-6 PUFA-derived bioactive lipid mediators were quantified by an unbiased liquid chromatography-tandem mass spectrometry lipidomic approach. Plasma was obtained from human subjects before and after 7 d of supplementation with pure n-3 DPA, n-3 EPA or placebo (olive oil). DPA supplementation increased the SPM resolvin D5
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.